Literature DB >> 24047216

Synthesis of aryl-substituted naphthalenoids as potent topoisomerase inhibitors.

Yan Shen, Wang Chen, Zhenyu Li, Yuemao Shen1.   

Abstract

Twelve new aryl-substituted naphthalenoids (1-7, 9, 10, and 13-16) together with four known ones (8, and 11- 13) have been designed and synthesized. Their antitumor activities were evaluated by sulforhodamine B assay on human breast cancer MDA-MB-231, human lung cancer A549 and human cervical cancer HeLa cell lines. Four compounds (2, 4, 10 and 12) showed potent inhibitory activities against the growth of the three cell lines with IC50 between 0.34-3.49 µM, and were more potent than the reference etoposide (IC50 3.67-13.78 µM). DNA relaxation assay revealed that compound 2 showed potent inhibitory activity against Topo IIα in vitro. The structure-activity relationships of these compounds were discussed, suggesting that further structural optimizations of aryl-substituted naphthalenoids could lead to the discovery of potent antitumor agents targeting topoisomerases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24047216     DOI: 10.2174/15734064113096660048

Source DB:  PubMed          Journal:  Med Chem        ISSN: 1573-4064            Impact factor:   2.745


  2 in total

1.  Dual Inhibition of Topoisomerase II and Tyrosine Kinases by the Novel Bis-Fluoroquinolone Chalcone-Like Derivative HMNE3 in Human Pancreatic Cancer Cells.

Authors:  Yong-Chao Ma; Zhi-Xin Wang; Shao-Ju Jin; Yan-Xin Zhang; Guo-Qiang Hu; Dong-Tao Cui; Jiang-Shuan Wang; Min Wang; Fu-Qing Wang; Zhi-Jun Zhao
Journal:  PLoS One       Date:  2016-10-19       Impact factor: 3.240

2.  Identification of HN252 as a potent inhibitor of protein phosphatase PPM1B.

Authors:  Zhiyuan Lu; Peng Xiao; Yuan Zhou; Zhenyu Li; Xiao Yu; Jinpeng Sun; Yuemao Shen; Baobing Zhao
Journal:  J Cell Mol Med       Date:  2020-10-13       Impact factor: 5.295

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.